The Long Run with Luke Timmerman
Timmerman Report
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
Episodes
Mentioned books
Mar 14, 2023 • 1h 6min
Ep131: Ryan Watts on Neuroscience Drug R&D
Ryan Watts, CEO of South San Francisco-based Denali Therapeutics, on neuroscience drug discovery and development.
Feb 28, 2023 • 1h 9min
Ep130: David Hallal on a Life in Biotech & the Cell Therapy Wave
David Hallal, CEO of ElevateBio, on a long career in biotech and the coming 50-year opportunity in cell therapy and gene therapy.
4 snips
Feb 14, 2023 • 1h 12min
Ep129: Joanne Smith-Farrell on Engineered B-Cell Therapies
Joanne Smith-Farrell, CEO of Cambridge, Mass.-based Be Biopharma, on Engineered B-Cell Therapies for Cancer & Rare Diseases.
Feb 1, 2023 • 1h 1min
Ep128: Rick Berke on Building a Biotech Journalism Outlet to Last
Rick Berke, co-founder and executive editor of STAT, on building a biotech journalism outlet to last.
Jan 20, 2023 • 1h 10min
Ep127: Jeb Keiper on Computational Drug Discovery
Jeb Keiper, CEO of Nimbus Therapeutics, on computational drug discovery, an unusual business model, and an important new Tyk2 inhibitor for psoriasis and other forms of autoimmunity.
Jan 3, 2023 • 1h 12min
Ep126: DA Wallach on Becoming a Biotech VC
DA Wallach, founder and general partner of TIME Bioventures, on becoming a biotech venture investor.
Dec 19, 2022 • 1h 5min
Ep125: Barry Greene on a New Drug for Depression
Barry Greene, CEO of Cambridge, Mass.-based Sage Therapeutics, on plans to introduce a new type of treatment for depression and postpartum depression.
Nov 8, 2022 • 1h 10min
Ep124: Shehnaaz Suliman on Delivery of Genetic Medicines
Shehnaaz Suliman, CEO of ReCode Therapeutics, on lipid nanoparticle delivery of genetic medicines.
Oct 27, 2022 • 1h 15min
Ep123: Tariq Kassum on Single-Cell Analysis for Drug Discovery
Tariq Kassum, CEO of Cambridge, Mass.-based Celsius Therapeutics, on using single cell technology for drug discovery.
Oct 11, 2022 • 1h
Ep122: Aetna Wun Trombley on Extracellular Protein Degraders
Aetna Wun Trombley, CEO of Lycia Therapeutics, on extracellular protein degraders.
